Otonomy (OTIC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of diseases and disorders of the ear. It
Full IPO calendar & reports HERE. In order of largest IPO first. (1) Based in San Diego, CA, Otonomy (OTIC) scheduled an $80 million IPO on the Nasdaq with a market
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
| Website: | www.otonomy.com |
| Email: | ir@otonomy.com |
| Main Phone: | +1 619 323-2200 |
| Address: | 4796 Executive Drive |
| Address 2: | Suite 100 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NGS |
| CEO: | David A. Weber |
| Employees: | 56 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Otonomy (OTIC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of diseases and disorders of the ear. It
Full IPO calendar & reports HERE. In order of largest IPO first. (1) Based in San Diego, CA, Otonomy (OTIC) scheduled an $80 million IPO on the Nasdaq with a market
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
